Literature DB >> 11478583

Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes.

H Le Buanec1, C Vetu, A Lachgar, M A Benoit, J Gillard, S Paturance, J Aucouturier, V Gane, D Zagury, B Bizzini.   

Abstract

Anti-Tat vaccination experiments were carried out in mice with a view to inducing systemic in addition to mucosal immunity. For this, three types of immunizing preparations were tested, which consisted of Tat toxoid embedded in either an adjuvant oily structure (IMS), or nanoparticles of chitosan, or microparticles of polylactide-co-glycolide (PLG). Administered by either the intranasal or oral route all preparations triggered anti-Tat IgG and IgA antibodies. Sera from mice immunized with either of these preparations could also inhibit significantly the Tat transactivating activity. These results open up a new avenue to the development of an effective anti-AIDS protective vaccine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478583     DOI: 10.1016/s0753-3322(01)00073-7

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  4 in total

1.  Transport of chitosan-DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes.

Authors:  Irina Kadiyala; Yihua Loo; Krishnendu Roy; Janet Rice; Kam W Leong
Journal:  Eur J Pharm Sci       Date:  2009-11-12       Impact factor: 4.384

2.  Nanotechnology Applications to HIV Vaccines and Microbicides.

Authors:  Sandhya Boyapalle; Subhra Mohapatra; Shyam Mohapatra
Journal:  J Glob Infect Dis       Date:  2012-01

Review 3.  Demystifying particle-based oral vaccines.

Authors:  Pedro Gonzalez-Cruz; Harvinder Singh Gill
Journal:  Expert Opin Drug Deliv       Date:  2021-07-06       Impact factor: 8.129

4.  Chitosan microparticles loaded with yeast-derived PCV2 virus-like particles elicit antigen-specific cellular immune response in mice after oral administration.

Authors:  Sergio A Bucarey; Myriam Pujol; Joaquín Poblete; Ignacio Nuñez; Cecilia V Tapia; Andrónico Neira-Carrillo; Jonatán Martinez; Oliver Bassa
Journal:  Virol J       Date:  2014-08-20       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.